North America Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)
The North America Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US$ 147,317.2 million by 2031, up from US$ 12,583.7 million in 2024, with an estimated compound annual growth rate (CAGR) of 34.5% from 2025 to 2031.
Executive Summary and Market Analysis
The North American anti-obesity drugs market encompasses the United States, Canada, and Mexico, and is expected to capture a substantial portion of the global market. The growth in this region is driven by increasing obesity rates, heightened health awareness, and advancements in pharmaceutical research. The prevalence of obesity in North America is notably high, attributed to sedentary lifestyles, poor dietary choices, and genetic predispositions, which has led to a rising demand for effective weight management solutions. Additionally, government and healthcare initiatives aimed at obesity prevention and treatment are further propelling market growth. Improved healthcare access and insurance coverage for obesity treatments also encourage patients to adopt these medications. Innovations in technology and the development of safer, more effective drugs, particularly GLP-1 receptor agonists, have significantly improved treatment outcomes, earning the trust of healthcare providers and patients. Furthermore, increased investment in research and development by pharmaceutical companies, along with strategic partnerships for drug development and marketing, is contributing to the rapid expansion of the market. These factors position North America as a key player in the global anti-obesity drug market.
Strategic Insights
Market Segmentation Analysis
The global anti-obesity drugs market is primarily driven by the increasing prevalence of obesity. As obesity rates rise due to lifestyle factors and genetic influences, the demand for effective medical interventions is growing. This trend is prompting patients and healthcare providers to seek pharmacological solutions alongside lifestyle modifications. Consequently, pharmaceutical companies are investing heavily in the development and marketing of anti-obesity drugs. The World Health Organization (WHO) reports that the global prevalence of obesity has more than doubled since 1990, with 2.5 billion adults classified as overweight and over 890 million as obese in 2022. The prevalence of obesity is expected to rise from 14% in 2023 to 24% by 2035, affecting nearly 2 billion individuals. The economic burden of obesity is also significant, with costs projected to exceed US$ 4 trillion by 2035, accounting for about 3% of global GDP.
Country Insights
The North American market is segmented into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. According to the National Health and Nutrition Examination Survey, the obesity prevalence in U.S. adults was 40.3% from August 2021 to August 2023, with higher rates among those aged 40-59. This increase in obesity rates has led to a rise in related health issues, such as type 2 diabetes and cardiovascular diseases, driving demand for effective anti-obesity medications.
Key pharmaceutical companies, such as Novo Nordisk and Eli Lilly, have introduced innovative treatments that have transformed the market. Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, are widely prescribed for diabetes and obesity management. Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, has also gained traction, with promising results from clinical trials for new weight-loss drugs.
Company Profiles
Key players in the North America Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.
Executive Summary and Market Analysis
The North American anti-obesity drugs market encompasses the United States, Canada, and Mexico, and is expected to capture a substantial portion of the global market. The growth in this region is driven by increasing obesity rates, heightened health awareness, and advancements in pharmaceutical research. The prevalence of obesity in North America is notably high, attributed to sedentary lifestyles, poor dietary choices, and genetic predispositions, which has led to a rising demand for effective weight management solutions. Additionally, government and healthcare initiatives aimed at obesity prevention and treatment are further propelling market growth. Improved healthcare access and insurance coverage for obesity treatments also encourage patients to adopt these medications. Innovations in technology and the development of safer, more effective drugs, particularly GLP-1 receptor agonists, have significantly improved treatment outcomes, earning the trust of healthcare providers and patients. Furthermore, increased investment in research and development by pharmaceutical companies, along with strategic partnerships for drug development and marketing, is contributing to the rapid expansion of the market. These factors position North America as a key player in the global anti-obesity drug market.
Strategic Insights
Market Segmentation Analysis
- By Type: The market is divided into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.
- By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.
- By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominate the market in 2024.
- By GLP-1 Agonist: Further segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide having the largest share in 2024.
- By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading in 2024.
- By Route of Administration: Divided into Oral and Parenteral, with Parenteral being the most prevalent in 2024.
- By Distribution Channel: Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share in 2024.
The global anti-obesity drugs market is primarily driven by the increasing prevalence of obesity. As obesity rates rise due to lifestyle factors and genetic influences, the demand for effective medical interventions is growing. This trend is prompting patients and healthcare providers to seek pharmacological solutions alongside lifestyle modifications. Consequently, pharmaceutical companies are investing heavily in the development and marketing of anti-obesity drugs. The World Health Organization (WHO) reports that the global prevalence of obesity has more than doubled since 1990, with 2.5 billion adults classified as overweight and over 890 million as obese in 2022. The prevalence of obesity is expected to rise from 14% in 2023 to 24% by 2035, affecting nearly 2 billion individuals. The economic burden of obesity is also significant, with costs projected to exceed US$ 4 trillion by 2035, accounting for about 3% of global GDP.
Country Insights
The North American market is segmented into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. According to the National Health and Nutrition Examination Survey, the obesity prevalence in U.S. adults was 40.3% from August 2021 to August 2023, with higher rates among those aged 40-59. This increase in obesity rates has led to a rise in related health issues, such as type 2 diabetes and cardiovascular diseases, driving demand for effective anti-obesity medications.
Key pharmaceutical companies, such as Novo Nordisk and Eli Lilly, have introduced innovative treatments that have transformed the market. Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, are widely prescribed for diabetes and obesity management. Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, has also gained traction, with promising results from clinical trials for new weight-loss drugs.
Company Profiles
Key players in the North America Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. NORTH AMERICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 North America Anti-Obesity Drugs Market Forecast and Analysis
7. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. NORTH AMERICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 North America
14.1.1 North America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 North America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 United States: North America Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 United States: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 United States: North America Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 United States: North America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.1.2.2.5 United States: North America Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 United States: North America Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 United States: North America Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 Canada: North America Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 Canada: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 Canada: North America Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 Canada: North America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 Canada: North America Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 Canada: North America Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 Canada: North America Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 Mexico: North America Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 Mexico: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 Mexico: North America Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 Mexico: North America Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.3.4.4.5 Mexico: North America Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 Mexico: North America Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 Mexico: North America Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. NORTH AMERICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 North America Anti-Obesity Drugs Market Forecast and Analysis
7. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. NORTH AMERICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 North America
14.1.1 North America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 North America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 United States: North America Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 United States: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 United States: North America Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 United States: North America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.1.2.2.5 United States: North America Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 United States: North America Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 United States: North America Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 Canada: North America Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 Canada: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 Canada: North America Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 Canada: North America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 Canada: North America Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 Canada: North America Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 Canada: North America Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 Mexico: North America Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 Mexico: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 Mexico: North America Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 Mexico: North America Anti-Obesity Drugs Market Share - by Glp-1 Agonist
14.3.4.4.5 Mexico: North America Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 Mexico: North America Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 Mexico: North America Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
LIST OF TABLES
Table 1. North America Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Heat Map Analysis by Key Players
Table 1. North America Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. North America Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. North America Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. North America Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. North America Anti-Obesity Drugs Market Share (%) - by Glp-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. North America Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. North America Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. North America Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. North America Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Company Positioning & Concentration
Figure 1. North America Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. North America Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. North America Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. North America Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. North America Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. North America Anti-Obesity Drugs Market Share (%) - by Glp-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. North America Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. North America Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. North America Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. North America Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Company Positioning & Concentration
